The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo

A phase 2 clinical trial investigating the efficacy and safety of AS602801, a newly developed JNK inhibitor, in the treatment of inflammatory endometriosis is complete. We are now examining whether AS602801 acts against human cancer cells in vitro and in vivo. In vitro, AS602801 exhibited cytotoxici...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Okada, Masashi, Kuramoto, Kenta, Takeda, Hiroyuki, Watarai, Hikaru, Sakaki, Hirotsugu, Seino, Shizuka, Seino, Manabu, Suzuki, Shuhei, Kitanaka, Chifumi
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053629/
https://ncbi.nlm.nih.gov/pubmed/27027242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados